Novartis and GWQ, a group of German health insurers, are piloting an agreement that will see the Swiss pharma firm repay some of the cost of its CAR-T cell therapy Kymriah (tisagenlecleucel) if survival outcomes are not met. It is the first outcomes-based deal for an anticancer gene therapy and CAR-T therapy in Germany, say Novartis and GWQ.
With the aim of securing faster access for patients, the agreement will run until